Shots:

• The P-IIb trial evaluating zanidatamab (20mg/kg, IV, q2w) in 87 patients at 32 trial sites in 9 countries in North America, South America, Asia & EU
• The results showed a cORR (41.3%) with a KM estimated m-DoR (12.9mos.) with a median study follow-up time of 12.4mos. & m-PFS was 5.5mos. among 80 patients & rapid, durable responses with a manageable safety profile, CR (1%), PR (32%), SD (22%), PD (24%) & DCR (68.8%), no responses were reported in cohort 2. The results were published in The Lancet Oncology
• As the data cut off Oct 2022, ongoing responses (49%), DoR of ≥16wks. (81.8%) among 33 patients, the median time to first confirmed response was 1.8mos. along with a manageable & tolerable safety profile, 2.3% experienced AEs leading to treatment discontinuation

Ref: PRNewswire | Image: Jazz Pharmaceuticals 

Related News:- Jazz Pharmaceuticals Exercised its Option to Advance Zymeworks' Zanidatamab for Cancer Patients